Predicting when prostate cancer stops responding to hormone therapy
Part of Cancer, Kidney & urinary clinical trials.
This study uses a computer program to look at your prostate biopsy tissue and help predict when your cancer might stop responding to hormone therapy. This could help you and your doctor plan ahead for your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer is considered intermediate or high risk.
- You have had a biopsy of your prostate.
- You have been treated only with hormone therapy (not surgery or radiation).
- You do not have another cancer that you are getting systemic treatment for.
- You agree to take part in this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an artificial intelligence (AI) tool that may improve how doctors detect prostate cancer using imaging and biopsy information. It could help better identify cancer that is suspected based on PSA blood tests and rectal exam findings.
This study uses artificial intelligence to help doctors predict the best treatment for prostate cancer. It may help match you with the most effective care based on your specific situation.
This study uses an artificial intelligence (AI) system to look at prostate biopsy samples and predict if the cancer has spread to the lymph nodes. It may help doctors decide on the best treatment without needing extra surgery or scans.
This trial tests whether an artificial intelligence (AI) program can help doctors decide when a prostate biopsy is needed. It is for men who have had a prostate MRI that shows either a low-risk (PIRADS 1-2) or uncertain (PIRADS 3) spot, along with a higher-than-normal PSA level. You may qualify if you have certain risk factors like a high PSA density, suspicious digital rectal exam, or family history of prostate cancer.
This study uses artificial intelligence to examine MRI and other health data to better predict if high-risk prostate cancer has spread to nearby lymph nodes. Researchers hope this will help guide treatment decisions.
This study uses an artificial intelligence (AI) program to read MRI scans of the prostate and compare its findings with those of expert radiologists. The goal is to see if the AI can detect prostate cancer as accurately as the human experts, which might help in future diagnosis and treatment planning.
Hear when a new Prostatic Neoplasms, Castration-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.